Seroprevalence of Helicobacter pylori/CagA Antibodies in Guatemalan Gastric Cancer Patients: Association of Seropositivity with Increased Plasma Levels of Pepsinogens but not Soluble Urokinase Plasminogen Activator Receptor
| Autor: | Irmgardt Alicia Wellmann, Carmen I. Villagrán de Tercero, Clas Une, Rafael Fernandez-Botran, Ericka Méndez-Chacón, Bikash Bhandari, Elisa Hernandez Lopez de Rodas |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty 030231 tropical medicine Population Enzyme-Linked Immunosorbent Assay Gastroenterology digestive system Helicobacter Infections Receptors Urokinase Plasminogen Activator 03 medical and health sciences 0302 clinical medicine Antigen Bacterial Proteins Seroepidemiologic Studies Stomach Neoplasms Virology Internal medicine Pepsinogen A Helicobacter Medicine CagA Humans education Cancer education.field_of_study Antigens Bacterial biology Helicobacter pylori business.industry Case-control study Articles Middle Aged biology.organism_classification Guatemala bacterial infections and mycoses Antibodies Bacterial digestive system diseases Infectious Diseases SuPAR Case-Control Studies biology.protein Parasitology Female Antibody business Infection |
| Zdroj: | The American Journal of Tropical Medicine and Hygiene, vol.103(1), pp.260-265 Kérwá Universidad de Costa Rica instacron:UCR Am J Trop Med Hyg |
| Popis: | Infection by Helicobacter pylori is a major risk factor for gastric cancer (GC), the second leading cause of cancer-related death worldwide. Although biomarkers such as pepsinogens (PGs) and soluble urokinase plasminogen activator receptor (suPAR) may have diagnostic and/or prognostic value in patients with GC, their levels may be affected by H. pylori infection. The aim of this study was to investigate the association of the presence of antibodies to H. pylori and cytotoxin-associated gene A (CagA) with plasma levels of PGs and suPAR in a cohort of Guatemalan GC patients and controls. To this end, levels of suPAR, Pepsinogens I and II (PGI and PGII), and antibodies to H. pylori and CagA toxin were determined by ELISA in plasma samples from 67 GC patients and 136 matched healthy controls. Seropositivity for CagA was significantly higher in patients with GC than in controls. Pepsinogens II and suPAR levels were higher and PGI/PGII ratios were lower in GC patients than in controls. There was a significant association of H. pylori seropositivity status with increased levels of PGII and lower PGI/PGII ratios, particularly in the control (non-GC) population. The levels of suPAR were not significantly affected by H. pylori or CagA seropositivity status. These results suggest that the seropositivity status for H. pylori and CagA need to be taken into account during the GC diagnostic process. UCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Instituto de Investigaciones en Salud (INISA) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|